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Abstract
Introduction Aberrant methylation of CpG islands is a hallmark
of cancer and occurs at an early stage in breast tumorigenesis.
However, its impact on tumor development is not fully
determined, and its potential as a diagnostic biomarker remains
to be validated. Methylation profiling of invasive breast
carcinoma has been largely explored. Conversely, very little and
sparse information is available on early-stage breast cancer. To
gain insight into the epigenetic switches that may promote and/
or contribute to the initial neoplastic events during breast
carcinogenesis, we have analyzed the DNA methylation profile
of ductal carcinoma in situ, a premalignant breast lesion with a
great potential to progress toward invasive carcinoma.
Methods We have utilized a comprehensive and sensitive array-
based DNA mapping technique, the methylated-CpG island
recovery assay, to profile the DNA methylation pattern in ductal
carcinoma in situ. Differential methylation of CpG islands was
compared genome-wide in tumor DNA versus normal DNA
utilizing a statistical linear model in the LIMMA software
package.
Results Using this approach, we have identified 108 significant
CpG islands that undergo aberrant DNA methylation in ductal
carcinoma in situ and stage I breast tumors, with methylation
frequencies greater than or comparable with those of more
advanced invasive carcinoma (50% to 93%). A substantial
fraction of these hypermethylated CpG islands (32% of the
annotated CpG islands) is associated with several homeobox
genes, such as the TLX1, HOXB13, and HNF1B genes. Fifty-
three percent of the genes hypermethylated in early-stage
breast cancer overlap with known Polycomb targets and include
homeobox genes and other developmental transcription factors.
Conclusions We have identified a series of new potential
methylation biomarkers that may help elucidate the underlying
mechanisms of breast tumorigenesis. More specifically, our
results are suggestive of a critical role of homeobox gene
methylation in the insurgence and/or progression of breast
cancer.
Introduction
Breast cancer is a leading cause of cancer-related mortality in
women, claiming over 400,000 lives per year worldwide. At
the current breast cancer incidence rates, one in eight women
is expected to develop the disease in her lifetime [1]. In spite
of the high frequency, however, more than 90% of the breast
cancer patients will survive if cancer is detected at an early
stage and if treatment is begun promptly. Early detection is
therefore extremely crucial for successful treatment and favo-
rable prognosis, and emphasizes the need for new screening
strategies for prompt intervention.
It is now widely recognized that aberrant epigenetic modifica-
tions play a crucial role in altering gene expression and induc-
ing tumor formation [2]. Methylation of CpG-rich islands
encompassing gene promoter regions is especially relevant
for the silencing of important tumor suppressor genes and
accounts for a growing number of diseases, including breast
cancer [3-5]. Several genes involved in cell cycle regulation
and apoptosis (CCND2, CDKN2A/p16, RASSF1A), DNA
damage response (BRCA1), cell adhesion (CDH1) and cell
signaling (ER, RAR 2) have been reported to undergo pro-
moter hypermethylation in breast carcinoma as well as in other
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tumor types [6-10]. High levels of some hypermethylated
genes can be detected very early, in the ductal lavage and nip-
ple aspirates of patients with ductal carcinoma in situ (DCIS)
(a stage 0 breast cancer) and stage I tumors, with methylation
frequencies comparable with those of more advanced, inva-
sive breast cancers [11]. Epigenetic inactivation can also
occur, at different levels depending on the gene examined, in
benign diseases such as mammary epithelial hyperplasia and
intraductal papillomas – but not in disease-free normal breast
epithelium, proliferating lactating breast tissue or stromal cells
[12]. In some cases, even the normal breast tissue adjacent to
the tumor site can display high levels of promoter methylation,
indicating that premalignant epigenetic changes have the
potential to spread gradually from the tumor epicenter to the
surrounding cells or that a field defect exists that promotes
tumorigenesis [13,14]. These data altogether support the evi-
dence that methylation-driven gene silencing is a frequent as
well as a relatively early event in breast tumorigenesis and can
be used as a tag to detect breast cancer lesions at their very
first appearance.
Based on this assumption, several groups have attempted, in
recent years, to establish multigene DNA methylation profiles
for the detection and classification of breast cancer. Their
studies were mostly restricted to methylation-specific PCR
analysis or to the array-based screening of limited target pan-
els, and thus failed to interrogate the entire 30,000 CpG
island repertoire of the genome [12,15-20]. In addition, these
studies as well as genome-wide DNA methylation mapping
techniques were usually employed to scrutinize invasive and
metastatic breast carcinomas (stage II tumors and higher) [21-
25]. These screening methods clearly overlook early epige-
netic changes that may precede and/or promote invasive
growth formation and offer limited diagnostic applications.
Given the scattered and inadequate information available on
early-stage breast tumors, it is not surprising that the search
for breast cancer-specific methylation biomarkers has barely
been translated into new reliable screening tests for the
women at risk.
To fill the gaps in this area of research, we have analyzed the
global methylation profile of DCIS, a premalignant breast
lesion with a high potential to progress toward invasive and
metastatic carcinoma, through loss of the myoepithelial cell
layer [26]. For DNA methylation analysis, we have utilized a
high-throughput methodology, recently developed in our labo-
ratory. The methylated-CpG island recovery assay (MIRA) is a
very sensitive technique that exploits the strong affinity of the
MBD2/MBD3L1 complex to double-stranded CpG-methyl-
ated DNA and allows one to detect cell-type-dependent differ-
ences in DNA methylation on a microarray platform [27,28].
We have applied this technology to identify a series of novel
candidate tumor suppressor genes and potential DNA methyl-
ation biomarkers in DCIS. The present study provides an
unprecedented snapshot of the global methylation profile in
early-stage breast carcinoma (approximately 28,000 CpG
islands were analyzed) and may lead to more accurate diag-
nostic tests for the prediction of breast cancer. Moreover, this
work draws attention to the potential role of DNA methylation
in the misregulation of homeobox genes during breast tumori-
genesis. Homeobox-containing transcription factors control
vital functional networks during tissue development and differ-
entiation, and their aberrant expression has been often associ-
ated, in the mammary gland, with both morphological
abnormalities and oncogenesis [29-31].
Materials and methods
Specimens
Breast cancer samples of different histological type and grade
were obtained from the City of Hope frozen tumor bank (City
of Hope, Duarte, CA, USA). Tumors were staged according to
the American Joint Committee on Cancer staging system pro-
tocol [32]. Tissue sections, derived from various DCIS speci-
mens, were stained with H&E and were reviewed by a
pathologist to confirm the presence and the extent of the
lesions. Breast tissue obtained from non-neoplastic breast
quadrants served as the normal control. All patients gave writ-
ten informed consent and authorization for use of biological
specimens. The present study was approved by the Institu-
tional Review Board of the City of Hope Medical Center (IRB#
97134).
Methylated-CpG island recovery assay-assisted 
microarray analysis
The MIRA and microarray analysis were performed as previ-
ously described with some modifications [27,28]. Genomic
DNA was isolated from intraductal carcinomas (DCIS) and
from matching normal tissues using either standard phenol–
chloroform extraction methods or the DNeasy purification kit
(Qiagen, Valencia, CA, USA). Between 0.5 and 1 g DNA
were double-digested with MseI (5'-TTAA) and HhaI (5'-
GCGC), to allow selective collection of substantially methyl-
ated CpG islands. Digested DNA was then incubated with a
mixture of purified GST-tagged MBD2b and His-tagged
MBD3L1 proteins (1:1) preincubated and bound to Mag-
neGST glutathione particles (TM240; Promega, Madison, WI,
USA). Binding reactions were carried out overnight at 4°C on
a rocking platform, in 1× MIRA binding buffer (10 mM Tris–
HCl (pH 7.5), 50 mM NaCl, 1 mM ethylenediamine tetraacetic
acid, 1 mM dithiothreitol, 3 mM MgCl2, 0.1% Triton-X100, 5%
glycerol, 25 g/ml BSA, and sonicated JM110 (dcm minus)
bacterial DNA). Pelleted glutathione beads were washed three
times with a high salt-washing buffer (containing 700 mM
NaCl), and the methylated DNA-enriched genomic DNA frac-
tion was eluted with a guanidinium hydrochloride-containing
buffer. DNA purification was carried out using the Qiaquick
PCR purification kit according to the manufacturer's instruc-
tions (Qiagen).Available online http://breast-cancer-research.com/content/11/1/R14
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Following the MIRA pulldown, CpG-enriched DNA fragments
were ligated to MseI linkers (upper strand sequence, 5'-
AGCAACTGTGCTATCCGAGGGAT; lower strand
sequence, 5'-TAATCCCTCGGA) and were PCR-amplified for
up to 20 cycles by real-time PCR. Two micrograms each of the
amplicons from MIRA-enriched tumor DNA and from MIRA-
enriched normal control samples were labeled with Cy5-dCTP
and Cy3-dCTP respectively (GE Healthcare Bio-Sciences
Corp., Piscataway, NJ, USA), using a BioPrime Array CGH
Genomic Labeling kit (Invitrogen, Carlsbad, CA, USA). The
purified samples were then mixed, and hybridized to CpG
island microarrays, according to the Agilent ChIP-on-chip pro-
tocol (version 9.0; Agilent Technologies, Santa Clara, CA,
USA). Human CpG island microarrays contain 237,000 oligo-
nucleotide probes covering 27,800 CpG islands and were
purchased from Agilent Technologies (Santa Clara, CA, USA).
Microarray data analysis
Following hybridization and washing (Agilent ChIP-on-chip
protocol, version 9.0), microarray slides were scanned using
an Axon GenePix 4000b scanner (Molecular Devices, Sunny-
vale, CA, USA) and images were quantified by GenePix Pro 6
software (Molecular Devices, Sunnyvale, CA, USA). Preproc-
essing of raw data and statistical analysis were performed as
previously described with some modifications [33]. Log2-
transformed ratios on each array were analyzed separately.
Probes were selected as positive if their ratios fell into more
than the 98th percentile range on the array. Methylation
regions (peaks) were defined as regions that contain a mini-
mum of three positive probes. One negative probe was
allowed within the peak as long as it was not present at the
end of the region. The average of the log2 ratios of the positive
probes within each peak was assigned as the peak score.
Peaks were then annotated based on their location relative to
known transcripts (UCSC hg18 refseq). Peaks overlapping
with the ±1,000 bp region of a known transcription start site
to -10 kb of the transcription start site were annotated as
upstream of the transcript, and peaks that overlap with the
±1,000 bp region of a known transcription termination site to
+10 kb downstream of the transcription termination site were
annotated as downstream of the transcript. Peaks falling into
known transcripts but not within 1,000 bp of either the tran-
scription start site or the transcription termination site were
denoted intragenic.
The transcripts that have either upstream, intragenic or down-
stream peaks in at least three out of six DCIS samples were
selected as interesting targets, and are reported in Table 1.
For peaks that fell into uncharacterized regions of the genome,
the location of the CpG island was used instead (Table 2).
Microarray data were deposited in the Gene Expression Omni-
bus repository [GEO:GSE14865].
Combined bisulfite restriction analysis and bisulfite 
sequencing
Total genomic DNA was isolated from human breast carci-
noma and from normal tissues as described above. To analyze
the methylation status of cytosines in several hypermethylated
microarray targets, DNA (1 g) was treated with sodium
bisulfite according to the manufacturer's protocol (EpiTect;
Qiagen) and was subjected to combined bisulfite restriction
analysis [34]. The PCR primer sequences used to amplify the
candidate genes in bisulfite-treated DNA are available upon
request. HeLa DNA was methylated in vitro with M. SssI meth-
yltransferase and served as a positive control. For sequence
analysis, the PCR products obtained after bisulfite conversion
were cloned into the TOPO-TA cloning vector (Invitrogen) and
up to 12 individual clones were sequenced.
Results
Genome-wide detection of methylated CpG islands in 
DCIS
The MIRA, used in combination with microarray analysis, is a
high-resolution mapping technique and has proven successful
in profiling global DNA methylation patterns in lung cancer
[33,35]. In the present study we have applied this sensitive
method to establish the methylation status of CpG islands in
early-stage ductal carcinoma and to investigate its potential
role in the initiation and development of breast cancer. Six
DCIS were screened for methylation by MIRA-based microar-
rays. To ensure consistency with the initial clinical diagnosis,
and the presence of epithelial cells in the sample, histological
examination of the specimens (both cancer samples and their
matching normal) was conducted with the help of a
pathologist.
The H&E slides derived from tumor samples displayed a pre-
dominant DCIS component (70% to 80%) over normal stro-
mal tissue and infiltrating lymphocytes (as shown for DCIS
number 4 in Figure 1, upper right panel). Since contamination
with low amounts of normal cells is not expected to interfere
with the overall interpretation of the methylation data, tumor
specimens were not subjected to further microdissection. Nor-
mal healthy breast tissues adjacent to the lesions and obtained
at the time of the surgical resection were used as a control.
When matching normal tissue was not available, a DNA mix-
ture from several normal breast tissues was used as a control.
To avoid epigenetic variations due to age, reproductive state
and/or cancer stage, we pooled together, whenever possible,
DNA of normal breast tissues derived from comparable donors
(same age frame, tumor stage, estrogen receptor/progester-
one receptor status, and so forth).
Genomic DNA isolated from DCIS and normal tissue was sub-
jected to MIRA enrichment, labeling, and subsequent microar-
ray analysis, as depicted in detail in Figure 1. DCIS-specific
methylation regions (peaks) were defined using stringent sta-
tistical criteria, and a full description of the algorithm used forBreast Cancer Research    Vol 11 No 1    Tommasi et al.
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Table 1
Methylated target genes identified by methylated-CpG island recovery assay-assisted microarray analysis
Target number Gene Description Gene location Strand Position relative to 
genea
Average ratiob Count
1* FOXE1 Forkhead box E1 Chr9: 99655357 to 
99658818
+ Downstream 13.76 4
2 SEMA6C Semaphorin 6C Chr1: 149370786 to 
149385728
- Downstream 6.40 4
3* HNF1Bc Hnf1 homeobox B Chr17: 33120546 to 
33179209
-U p s t r e a m 6 . 0 6 4
4 OTX1 Orthodenticle homeobox 1 Chr2: 63131468 to 
63137816
+ Intragenic 4.83 4
5* TLX1 T-cell leukemia homeobox 1 Chr10: 102881050 
to 102887535
+ Intragenic 4.50 4
6 ESAM Endothelial cell adhesion 
molecule
Chr11: 124128228 
to 124137433
- Intragenic 4.16 4
7* CNTNAP1 Contactin associated protein 1 Chr17: 38088158 to 
38105358
+ Intragenic 3.94 4
8* GFI1 Growth factor independent 1 
transcription repressor
Chr1: 92712905 to 
92725021
- Intragenic 3.64 4
9* RASL10A Ras-like, family 10, member A Chr22: 28038921 to 
28041748
- Intragenic 3.42 4
10* IFNA8 Interferon, alpha 8 Chr9: 21399146 to 
21400184
+U p s t r e a m 3 . 4 1 4
11 ERGIC2 Ergic and golgi 2 Chr12: 29384845 to 
29425410
-U p s t r e a m 3 . 3 9 4
12 PCDH7 Protocadherin 7 Chr4: 30331134 to 
30757519
+ Intragenic 3.16 4
13 RASGRP2 Ras guanyl releasing protein 2 Chr11: 64250958 to 
64269504
- Intragenic 3.01 4
14 NFATC1 Nuclear factor of activated T-
cells 1
Chr18: 75256759 to 
75390311
+ Intragenic 2.93 4
15 RLTPR Rgd motif, leucine-rich repeats, 
tropomodulin domain and 
proline-rich containing gene
Chr16: 66236530 to 
66248973
+ Intragenic 2.75 4
16 AK123344 Hypothetical gene Chr10: 102979341 
to 102985256
+ Downstream 16.49 3
17 C1orf114 Chromosome 1 open reading 
frame 114
Chr1: 167630737 to 
167663294
- Upstream 11.13 3
18 TRPS1 Trichorhinophalangeal 
syndrome I
Chr8: 116489899 to 
116750402
- Intragenic 11.07 3
19 PCDHGA12 Protocadherin gamma 
subfamily A, 12
Chr5: 140790341 to 
140872730
+ Upstream 11.02 3
20 C14orf25 Chromosome 14 open reading 
frame 25
Chr14: 37150207 to 
37580397
+ Upstream 10.34 3
21 CDKN2A Cyclin-dependent kinase 
inhibitor 2A (P16)
Chr9: 21957750 to 
21984490
- Downstream 9.86 3
22 SCRT2 Scratch homolog 2, zinc finger 
protein
Chr20: 590240 to 
604823
- Downstream 9.47 3
23 BCOR Bcl6 co-repressor Chrx: 39795443 to 
39921526
-U p s t r e a m 9 . 4 3 3
24 KHDC1 Kh homology domain 
containing 1
Chr6: 74007759 to 
74076659
-U p s t r e a m 9 . 0 0 3
25* NXPH1 Neurexophilin 1 Chr7: 8440109 to 
8759118
+ Intragenic 8.83 3Available online http://breast-cancer-research.com/content/11/1/R14
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26 CNR1 Cannabinoid receptor 1 (brain) Chr6: 88910156 to 
88932281
-U p s t r e a m 8 . 7 8 3
27 BC039088 Hypothetical gene Chr5: 43050280 to 
43054670
-U p s t r e a m 8 . 6 1 3
28 EVX2 Even-skipped homeobox 2 Chr2: 176653080 to 
176656936
- Downstream 8.43 3
29* MT1E Metallothionein 1E Chr16: 55217085 to 
55218525
+U p s t r e a m 8 . 3 6 3
30* NR2F2 Nuclear receptor subfamily 2, 
group F, member 2
Chr15: 94674950 to 
94683047
+ Downstream 8.24 3
31 HOXC13 Homeobox C13 Chr12: 52618843 to 
52626595
+U p s t r e a m 8 . 0 8 3
32 HOXD8 Homeobox D8 Chr2: 176702722 to 
176704974
+U p s t r e a m 7 . 9 7 3
33 SYCP2L Synaptonemal complex protein 
2-like
Chr6: 10995049 to 
11082527
+U p s t r e a m 7 . 5 8 3
34 PCDHGB6 Protocadherin gamma 
subfamily B, 6
Chr5: 140767953 to 
140872730
+ Intragenic 7.37 3
35 ACTA1 Actin, alpha 1, skeletal muscle Chr1: 227633615 to 
227636466
-U p s t r e a m 7 . 3 6 3
36* PRDM14 Pr domain containing 14 Chr8: 71126576 to 
71146116
- Intragenic 7.27 3
37* HOXB13 Homeobox B13 Chr17: 44157124 to 
44161110
- Intragenic 6.91 3
38 OTX2 Orthodenticle homeobox 2 Chr14: 56337177 to 
56346937
-U p s t r e a m 6 . 7 0 3
39 ZNF711 Zinc finger protein 711 Chrx: 84385652 to 
84415025
+U p s t r e a m 6 . 6 3 3
40* NR2E1 Nuclear receptor subfamily 2, 
group E, member 1
Chr6: 108593954 to 
108616706
+ Intragenic 6.44 3
41* TAC1 Tachykinin, precursor 1 Chr7: 97199206 to 
97207720
+U p s t r e a m 6 . 3 7 3
42* CPEB1 Cytoplasmic polyadenylation 
element binding protein 1
Chr15: 81009005 to 
81113783
-U p s t r e a m 5 . 9 9 3
43 NKAPL Nfkb activating protein-like Chr6: 28335076 to 
28336715
+U p s t r e a m 5 . 8 6 3
44 NKX6-2 Nk6 homeobox 2 Chr10: 134448309 
to 134449527
- Downstream 5.72 3
45* TGIF2 Tgfb-induced factor homeobox 
2
Chr20: 34635423 to 
34655766
+U p s t r e a m 5 . 6 0 3
46 CR596471 Hypothetical gene Chrx: 133511720 to 
133522094
+U p s t r e a m 5 . 5 6 3
47 EVX2 Even-skipped homeobox 2 Chr2: 176653080 to 
176656936
- Intragenic 5.55 3
48 AX747981 Hypothetical gene Chr8: 96148213 to 
96154324
-U p s t r e a m 5 . 4 8 3
49 ST8SIA3 St8 alpha-N-acetyl-neuraminide 
alpha-2,8-sialyltransferase 3
Chr18: 53170718 to 
53187159
+ Intragenic 5.47 3
50 WT1 Wilms tumor 1 Chr11: 32365900 to 
32413663
- Intragenic 5.40 3
51 BARHL2 Barh-like homeobox 2 Chr1: 90950167 to 
90955382
-U p s t r e a m 5 . 3 9 3
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52 IRX1 Iroquois homeobox 1 Chr5: 3649167 to 
3654517
+ Intragenic 5.39 3
53 KLF11 Kruppel-like factor 11 Chr2: 10101132 to 
10112414
+U p s t r e a m 5 . 2 6 3
54 HLXB9 Homeobox Hb9 Chr7: 156479507 to 
156496108
-U p s t r e a m 5 . 2 5 3
55 NKX2-8 Nk2 homeobox 8 Chr14: 36118966 to 
36121537
-U p s t r e a m 5 . 2 0 3
56 ZFP91 Zinc finger protein 91 homolog 
(mouse)
Chr11: 58103162 to 
58145091
+U p s t r e a m 5 . 0 7 3
57 LHX2 Lim homeobox 2 Chr9: 125813709 to 
125835263
+ Intragenic 5.04 3
58 MEIS1 Meis homeobox 1 Chr2: 66516036 to 
66653085
+ Downstream 5.00 3
59* PAX2 Paired box 2 Chr10: 102495457 
to 102579688
+ Intragenic 4.95 3
60* LHX9 Lim homeobox 9 Chr1: 196153139 to 
196165896
+ Intragenic 4.81 3
61 GRASP Grp1-associated scaffold 
protein
Chr12: 50687014 to 
50695938
+U p s t r e a m 4 . 7 8 3
62 LHX8 Lim homeobox 8 Chr1: 75366706 to 
75399806
+ Intragenic 4.77 3
63 HOXD12 Homeobox D12 Chr2: 176672775 to 
176673734
+U p s t r e a m 4 . 6 6 3
64 PAX5 Paired box 5 Chr9: 36828530 to 
37024476
- Intragenic 4.56 3
65 LBX1 Ladybird homeobox 1 Chr10: 102976722 
to 102978707
- Downstream 4.53 3
66 EGFR Epidermal growth factor 
receptor
Chr7: 55054218 to 
55242525
+U p s t r e a m 4 . 4 5 3
67 ODZ3 Odz, odd Oz/ten-m homolog 3 Chr4: 183302134 to 
183508463
+U p s t r e a m 4 . 4 0 3
68 TM7SF4 Transmembrane 7 superfamily 
member 4
Chr8: 105421230 to 
105438092
+U p s t r e a m 4 . 2 2 3
69 ZNF311 Zinc finger protein 311 Chr6: 29070573 to 
29081014
- Downstream 4.09 3
70 PCDH19 Protocadherin 19 Chrx: 99433297 to 
99551927
- Intragenic 4.06 3
71 FLJ45983 Hypothetical gene Chr10: 8132418 to 
8135453
-U p s t r e a m 3 . 8 4 3
72 AX747375 Hypothetical gene Chr19: 41955897 to 
41958529
+ Downstream 3.83 3
73 PPP2R2C Protein phosphatase 2 
regulatory subunit B, gamma 
isoform
Chr4: 6373205 to 
6525227
- Intragenic 3.58 3
74 EMX1 Empty spiracles homeobox 1 Chr2: 72998111 to 
73015528
+ Intragenic 3.57 3
75 PRKCSH Protein kinase C substrate 
80K-H
Chr19: 11407268 to 
11422782
+U p s t r e a m 3 . 5 6 3
76 FZD1 Frizzled homolog 1 Chr7: 90731718 to 
90736068
+ Intragenic 3.52 3
77 LBX2 Ladybird homeobox 2 Chr2: 74578151 to 
74583951
-U p s t r e a m 3 . 4 2 3
Table 1 (Continued)
Methylated target genes identified by methylated-CpG island recovery assay-assisted microarray analysisAvailable online http://breast-cancer-research.com/content/11/1/R14
Page 7 of 17
(page number not for citation purposes)
the analysis is provided in Materials and methods. Using this
approach, we generated a list of over 100 significant CpG
islands that display aberrant methylation in early-stage breast
cancer and were methylation-positive in at least three out of six
DCIS examined (Tables 1 and 2). Consistent with a potential
role in transcriptional silencing, anomalous levels of DNA
methylation were detected at the 5' end of known genes, in
proximity of promoter regions or further upstream. Numerous
CpG islands mapping to intragenic or downstream regions of
annotated genes, however, were also found to be heavily
methylated in DCIS (Table 1).
Verification of tumor-specific DNA methylation by 
combined bisulfite restriction analysis
We next confirmed tumor-specific methylation for several of
the targets identified through array analysis using the BstUI
combined bisulfite restriction analysis (COBRA) assay. In this
assay, bisulfite-converted DNA is PCR-amplified using gene-
specific primers and is then digested with the restriction endo-
nuclease BstUI, which recognizes the sequence 5'-CGCG.
Unmethylated restriction sites are converted to 5'-TGTG by
sodium bisulfite and PCR and resist BstUI digestion, whereas
methylated sites remain unchanged and are cleaved by the
enzyme. The digested fragments displayed on agarose gels
are thus indicative of methylated BstUI sites in the region
analyzed.
Representative examples of COBRA results are shown in Fig-
ure 2. Here, we have inspected the methylation status of the
candidate genes ranked numbers 5, 7, 8, 29, 40, 42 and 54
on the list of differentially methylated targets (corresponding to
T-cell leukemia homeobox 1 (TLX1), CNTNAP1, GFI1, MT1E,
NR2E1, CPEB1 and homeobox HB9 (HLXB9), respectively).
All seven CpG islands appear methylated with high specificity
(no or very little methylation detected in normal breast tissue)
in the DCIS analyzed, and with methylation frequencies rang-
ing from 50% to 83% depending on the target gene. No target
region scrutinized so far exhibited robust CpG methylation
across all six intraductal carcinomas (Table 1 and data not
shown). Interestingly, we noticed that one-third of the CpG
islands identified by microarray analysis (26 out of the 81
annotated hits) are associated with members of various home-
obox superfamilies (HOX, LHX, NKX, PAX, and so forth) and
are preferential targets of de novo methylation in early-stage
breast cancer. These master regulators control vital functional
networks during tissue development and differentiation, and
are misregulated in a variety of malignancies, including breast
cancer [29,36].
To explore this interesting finding in more detail, we then
focused our attention on several homeobox genes. Besides
the CpG islands associated with the TLX1 gene and with the
HLXB9 gene (Figure 2), we have examined the methylation
status of the HNF1B and HOXB13 candidate gene targets
(hit numbers 3 and 37, respectively). An uncharacterized CpG
island located on chromosome 7 (CGI 7:48 and hit number 5
in Table 2) was also selected for COBRA analysis. Although
some levels of methylation could be detected in normal tis-
sues, methylation of HOXB13, HNF1B, and CGI 7:48 CpG
islands was clearly more pronounced in intraductal carcino-
mas (Figure 3, upper panel and Figure 4). Considering that the
same matching controls were negative in other COBRA
assays (Figure 2), we can exclude that the methylation signal
observed here in normal samples is due to contamination with
neighboring cancer cells. Rather, distinct cell populations
within the normal breast tissue may display specific DNA
methylation profiles, as recently established [37]. Differential
promoter hypermethylation in benign breast epithelium derived
from cancer patients can also be a function of age in a gene-
specific manner [16,38]. Likewise, the occurrence of unmeth-
ylated alleles in the cancer samples may reflect the heteroge-
neity of CpG methylation within the cell populations of the
tumor itself, but also the presence of normal cells in the
specimens.
Confirmation of the methylation pattern in invasive 
breast tumors
To corroborate the DCIS-specific methylation profiles of TLX1,
CGI 7:48, HOXB13, and HNF1B, we then extended the
COBRA analysis to a series of primary breast tumors of differ-
78 HOXC13 Homeobox C13 Chr12: 52618842 to 
52626595
+ Intragenic 3.40 3
79 MT1A Metallothionein 1A Chr16: 55230078 to 
55231500
+U p s t r e a m 3 . 3 6 3
80 DLX5 Distal-less homeobox 5 Chr7: 96487637 to 
96492079
- Intragenic 3.06 3
81 LDOC1L Leucine zipper, downregulated 
in cancer 1-like
Chr22: 43267113 to 
43272669
- Intragenic 2.30 3
aFor definitions of upstream, intragenic, and downstream, see Materials and methods (Microarray data analysis). The transcripts that have either 
upstream, intragenic or downstream peaks in at least three out of six DCIS samples were selected as positive targets. *Gene targets verified by 
combined bisulfite restriction analysis assays or bisulfite sequencing. bAverage of the log2 ratios assigned to positive peaks across the six DCIS. 
cHomeobox genes are indicated in bold.
Table 1 (Continued)
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ent histological type and stage (Figures 3 and 5, lower panels
and Figure 4). The TLX1 CpG island was methylated in 13 out
of the 16 stage I breast tumors (81%) and in six out of the
eight stage II invasive carcinomas (75%). Likewise, the CpG
island located on chromosome 7 (CGI 7:48) was methylated
in almost every stage I tumor examined (93%) and in 15 out of
the 17 more advanced tumors (stages II and III tumors, 88%).
Of the 32 invasive breast carcinomas tested (15 cases of
stage I tumors, nine cases of stage II tumors and eight cases
of stage III tumors) 29 displayed higher levels of methylation
relative to their matching controls within the HOXB13 element
(91%), whereas the HNF1B CpG island was methylated in 21
tumor samples (66%) (partial COBRA data are shown in Fig-
ure 4). Stage I tumors already exhibited a significant degree of
methylation (87% for HOXB13 and 73% for HNF1B), con-
firming the rapid and early nature of epigenetic reprogramming
in breast cancer (Figure 4, representative COBRA analysis
and Table 3).
Rodriguez and colleagues have reported recently that hyper-
methylation of the HOXB13 gene is a late event in breast tum-
origenesis [39]. This apparent discrepancy with our results
can be ascribed to the different methods used for the analysis
(methylation-specific PCR versus our genome-wide DNA
Table 2
Methylated CpG islands not associated with known genes
Target number Symbol CpG island locationa Average ratiob Count
1 CGI 1:42 Chr1: 38714506 to 38714991 6.27 4
2 CGI 6:60 Chr6: 106535804 to 106536465 4.69 4
3 CGI 2:112 Chr2: 239419845 to 239420943 4.22 4
4 CGI 4:34 Chr4: 174658599 to 174659018 2.94 4
5* CGI 7:48 Chr7: 35460738 to 35461227 17.26 3
6 CGI 8:121 Chr8: 100054909 to 100056159 16.81 3
7 CGI 10:46b Chr10: 119484483 to 119484981 15.44 3
8 CGI 17:16 Chr17: 44182434 to 44182640 13.96 3
9 CGI 7:351 Chr7: 129205522 to 129209745 11.56 3
10 CGI 6:19 Chr6: 27755772 to 27755984 10.16 3
11 CGI 8:31 Chr8: 81968510 to 81968882 8.45 3
12 CGI 22:48 Chr22: 44655029 to 44655728 7.98 3
13 CGI 2:77 Chr2: 176639821 to 176640909 7.91 3
14 CGI 5:47 Chr5: 176039674 to 176040127 7.78 3
15 CGI 7:29 Chr7: 129210233 to 129210591 7.60 3
16 CGI 3:47 Chr3: 134875805 to 134876344 6.58 3
17* CGI 4:35 Chr4: 24699204 to 24699608 6.22 3
18 CGI 6:18 Chr6: 27571155 to 27571358 6.18 3
19 CGI 7:277 Chr7: 154857318 to 154860615 5.91 3
20 CGI 10:46 Chr10: 102409137 to 102409658 5.84 3
21 CGI 4:21 Chr4: 174657922 to 174658134 5.53 3
22 CGI X:92 Chrx: 136459742 to 136460985 4.81 3
23 CGI 22:18 Chr22: 47762399 to 47762664 4.15 3
24 CGI 1:130 Chr1: 199774402 to 199775940 3.77 3
25 CGI 5:26 Chr5: 3379328 to 3379645 3.42 3
26 CGI 5:87 Chr5: 134853297 to 134854395 3.16 3
27 CGI 8:72 Chr8: 1100465 to 1101480 2.35 3
aFor uncharacterized gene targets, CpG island location was assigned instead of gene location. bAverage of the log2 ratios assigned to positive 
peaks across the six DCIS. Targets with methylated peaks within the CpG island in at least three out of six DCIS samples were considered 
significant. *Unknown CpG islands verified by combined bisulfite restriction analysis assays or bisulfite sequencing.Available online http://breast-cancer-research.com/content/11/1/R14
Page 9 of 17
(page number not for citation purposes)
methylation profiling), the different specimens examined in the
two studies (invasive-stage breast carcinomas versus DCIS),
and the different location of the CpG islands on the HOXB13
gene (promoter versus an intragenic CpG island, target
number 37). Methylation of this intragenic CpG island is an
early event in breast cancer development and may precede
promoter methylation. Whether this intragenic CpG island
affects the HOXB13 gene expression remains to be seen.
Two additional targets, the growth factor transcriptional
repressor GFI1 gene (target number 8) and the nuclear recep-
tor NR2E1 gene (target number 40), were inspected to evalu-
ate the level of methylation in early-stage breast carcinomas. In
agreement with the MIRA results, we found that the GFI1 CpG
island was hypermethylated in 14 out of the 18 tumors exam-
ined (six DCIS and 12 stage I tumors, 78%) while the NR2E1
target region was methylated in 11 out of the 21 early-stage
Figure 1
Outline of the methylated-CpG island recovery assay-assisted CpG island microarray analysis Outline of the methylated-CpG island recovery assay-assisted CpG island microarray analysis. Prior to microarray analysis, tissue sections, derived 
from six independent ductal carcinomas in situ (DCIS) and their matching normal areas, were stained with H&E and validated by a pathologist. 
Genomic DNA derived from tumor specimens and matching normal tissue was then subjected to methylated-CpG island recovery assay (MIRA) pull-
down as described in Materials and methods. MIRA-enriched fractions were labeled with different dyes, mixed, and hybridized to CpG island-Agilent 
slides and the relative enrichment factors between different tissues were determined by statistical analysis.Breast Cancer Research    Vol 11 No 1    Tommasi et al.
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breast tumors (six DCIS and 15 stage I tumors, 52%) (Figure
4, partial data and Table 3).
To assess the extent of CpG methylation within the HOXB13,
HNF1B,  HLXB9  and CGI 7:48 target sequences, primary
breast tumors were also subjected to bisulfite DNA sequenc-
ing together with their matching normal tissues (DCIS case
number 57 and stage I case numbers 4b and 233). As
expected, there is an evident tendency towards increased
methylation in tumor-derived samples; the occurrence of early-
stage cancer-specific methylated CpGs is very significant (P
< 0.001, Fisher's exact test) (Figure 6).
Discussion
DCIS is suspected to be a direct, although not obligate, pre-
cursor of invasive breast cancer, and aberrant DNA methyla-
tion is believed to play a crucial role in breast tumorigenesis.
Considering that epigenetic changes often become apparent
in early phases of the disease, we speculated that the identifi-
cation of DCIS-specific methylated biomarkers might be cru-
cial to elucidate the molecular mechanisms underlying the
initiation and development of breast cancer and to conceive
effective strategies for early diagnosis.
To acquire valuable information into the epigenetic switches
that may promote and/or contribute to the initial neoplastic
events, we have analyzed the DNA methylation profile of DCIS,
on a MIRA-based CpG island microarray platform. This novel
and sensitive genome-wide screening approach has led to the
identification of 108 CpG islands that display aberrant levels
of DNA methylation in early breast lesions. Of the 81 CpG
islands associated with known genes, only 37 map to pro-
Figure 2
Verification of tumor-specific methylation of seven candidate target genes Verification of tumor-specific methylation of seven candidate target genes. These targets were identified by the MIRA-assisted microarray approach 
(target numbers 5, 7, 8, 29, 40, 42 and 54, corresponding to TLX1, CNTNAP1, GFI1, MT1E, NR2E1, CPEB1 and HLXB9, respectively; Table 1). 
Genomic DNA from ductal carcinomas in situ (T) and matching normal breast tissues (N) was treated with sodium bisulfite and the target CpG 
island sequences were amplified using gene-specific primers. Methylation was confirmed by a BstUI combined bisulfite restriction analysis assay, 
which produces digestion products when BstUI restriction sites are methylated and not converted by bisulfite. HeLa DNA was methylated in vitro 
with the SssI methyltransferase and served as a positive control (Meth. DNA, Methylated HeLa DNA). Vertical white arrows indicate hypermethylated 
alleles in the target sequence. ±, digestion was carried out with or without BstUI restriction enzyme; N/T, normal/tumor pairs. When matching normal 
tissue was not available, a DNA mixture derived from several normal breast tissues was used instead. M, DNA marker.Available online http://breast-cancer-research.com/content/11/1/R14
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moter regions or further upstream (46%). In agreement with
recently published data [40], more than one-half of the meth-
ylated CpG islands in normal genomes fall within the body of
the gene or in downstream regions. The functional role of
these intergenic and intragenic CpG-rich elements remains
obscure, but it has been suggested that they may constitute
short independent transcriptional units [40].
Several targets have been examined by conventional bisulfite
methods and found to be differentially methylated in multiple
breast tumors, in complete agreement with the MIRA results.
Most importantly, these gene candidates display methylation
frequencies ranging from 50% to 83% in DCIS and up to 93%
in stage I breast cancer, depending on the target gene, and
these candidates hold great promise, alone or in combination,
for future diagnostic applications. We were also able to iden-
tify several genes, such as CDKN2A, PCDHGB6, and WT1
(Table 1) well known to be methylated and transcriptionally
silent in breast cancer [10,23]. Many other 'conventional'
methylation markers, however, were not represented in our
data set. This apparent discrepancy with previous reports can
be ascribed, in part, to the different conditions utilized in micro-
array data analysis to define thresholds; consequently, some
genes may be classified as false negative simply because they
fall below the statistical cutoff points. Digestion of genomic
DNA, prior to the MIRA pull down, with the methylation-sensi-
tive endonuclease HhaI can also be crucial in excluding those
CpG islands that are not methylated at HhaI restriction sites
(5'-GCGC), although they are methylated at surrounding
CpGs within the target sequence. In addition, genes previ-
ously described as methylated in advanced-stage breast can-
cer may not be methylated in DCIS.
Surprisingly, most of the targets identified in the present study
have never been linked to epigenetic errors during breast car-
cinogenesis and may shed new light into the molecular mech-
anisms underlying the insurgence of breast cancer. The
employment of undissected breast tissue that fails to discern
the epigenetic contribution of the single cell subtypes and the
restricted number of DCIS used in the microarray analysis,
Figure 3
Methylation of an uncharacterized CpG island on chromosome 7 Methylation of an uncharacterized CpG island on chromosome 7. Six cases of ductal carcinoma in situ (DCIS) and 32 invasive breast tumors of dif-
ferent histological type and grade were analyzed for CpG methylation. The target CpG island (hit number 5, Table 2) was subjected to the BstUI 
combined bisulfite restriction analysis assay. N/T, normal/tumor pairs. Vertical arrows indicate tumor-specific methylation. Target number 201 is a 
stage II breast carcinoma. M, DNA marker; Meth. DNA, HeLa DNA methylated in vitro with SssI methyltransferase, serving as a positive control.Breast Cancer Research    Vol 11 No 1    Tommasi et al.
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however, may represent important limitations to this study and
need to be kept in consideration.
Apart from the potential discovery of novel tumor suppressor
genes and/or methylation biomarkers, relevant for a better
comprehension and management of the disease, the present
study has uncovered a broad epigenetic phenomenon that
occurs at the onset of breast cancer development. Interest-
ingly, we found that 32% of the total hypermethylated CpG
islands (26 out of the annotated 81 hits) are associated with
members of multiple homeobox gene subfamilies – a surpris-
ingly high percentage considering that, so far, only ~300
homeobox genes have been identified in the human genome
(roughly 1% of the presumed battery of protein-coding genes)
[41]. CpG methylation of homeobox genes has been sporadi-
cally observed during breast tumorigenesis; that is, methyla-
tion of the HOXB13 gene [39] and members of the HOXA
cluster [42,43]. The extent and the recurrence of this epige-
netic event in mammary carcinoma, however, have never been
emphasized until now. Robust and frequent methylation of
homeobox genes is not restricted to breast cancer, and occurs
at significant frequencies (~10% to 20% of all methylated
genes) in early-stage lung carcinoma [28,35] – suggesting a
common epigenetic pathway involving the homeobox gene
network. Yet, the diverse and nonidentical methylation spectra
exhibited by DCIS and stage I lung cancer at homeobox gene-
associated CpG islands cautions against the existence of a
common epigenetic phenotype among different tumor types.
This is not surprising since the pattern and function of the
homeobox gene networks are exclusive for a particular tissue
[44] and no specific expression and/or CpG-island methyla-
tion signatures across tumors have so far been reported.
We cannot deduce why homeobox genes become preferential
targets of aberrant CpG methylation during breast tumorigen-
esis and whether this extensive methylation can shift their
finely tuned homeostasis, thus triggering tumorigenesis, or is
merely associated with the neoplastic event. The widespread
and recurrent nature of this phenomenon, however, seems to
suggest that a common mechanistic pathway may exist in can-
Figure 4
Combined bisulfite restriction analysis in ductal carcinoma in situ and more advanced primary breast tumors Combined bisulfite restriction analysis in ductal carcinoma in situ and more advanced primary breast tumors. The NRN1, GFI1, HOXB13, HNF1B-
associated CpG islands were analyzed by Combined bisulfite restriction analysis in ductal carcinoma in situ (DCIS) and more advanced breast car-
cinoma. Three representative DCIS, seven stage I tumors, five stage II tumors and five stage III breast tumors are shown. The total number of speci-
mens analyzed per gene and the relative methylation frequencies are presented in Table 3. N/T, normal/tumor pairs; M, DNA marker; Meth. DNA, 
HeLa DNA methylated in vitro with SssI methyltransferase, serving as a positive control.Available online http://breast-cancer-research.com/content/11/1/R14
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cer cells, which promotes de novo methylation of these targets
at the onset of tumor development.
Recent data have unraveled the role of Polycomb repressor
complexes in targeting and modulating homeobox genes. At
least six independent genome-wide studies have identified
several common Polycomb targets in vertebrates and flies,
most of which are represented by homeobox genes and other
developmental transcription factors [45]. Interestingly, 43 out
of the 81 annotated genes identified in the present study
(~53%) and found to be hypermethylated in early-stage breast
cancer overlap with known Polycomb targets, strongly sup-
porting the PcG link [46]. Moreover, most of these DCIS-spe-
Figure 5
Methylation of the TLX1 gene in ductal carcinoma in situ and invasive primary breast tumors Methylation of the TLX1 gene in ductal carcinoma in situ and invasive primary breast tumors. Six cases of ductal carcinoma in situ (DCIS), 16 cases 
of stage I tumors, and eight cases of stage II tumors were analyzed. After sodium bisulfite treatment, the CpG island within the TLX1 gene was ampli-
fied with suitable primers and subjected to the BstUI combined bisulfite restriction analysis assay. Digested fragments on the gel are indicative of 
methylated BstUI restriction sites (5'-CGCG) within the CpG island. Vertical arrows indicate tumor-specific methylation in the target sequence. N/T, 
normal/tumor pairs; M, DNA marker; Meth. DNA, HeLa DNA methylated in vitro with SssI methyltransferase, serving as a positive control.
Table 3
Methylation frequencies of selected genes in ductal carcinoma in situ and invasive breast tumors
Ductal carcinoma in situ Stage I tumors Stage II tumors Stage III tumors
TLX1 4/6 (67%) 13/16 (81%) 6/8 (75%)
CGI 7:48 3/6 (50%) 14/15 (93%) 7/9 (78%) 8/8 (100%)
HOXB13 3/6 (50%) 13/15 (87%) 8/9 (89%) 8/8 (100%)
HNF1B 3/6 (50%) 11/15 (73%) 5/9 (56%) 5/8 (63%)
GFI1 5/6 (83%) 9/12 (75%) 7/8 (88%)
NR2E1 3/6 (50%) 8/15 (53%)Breast Cancer Research    Vol 11 No 1    Tommasi et al.
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Figure 6
Bisulfite sequencing data Bisulfite sequencing data. The extent of CpG methylation was determined for target sequences within (a) CGI 7:48, (b) HOXB13, (c) HNF1B, and 
(d) HLXB9 by sodium bisulfite sequencing. Primary breast tumors were subjected to bisulfite DNA sequencing together with their matching normal 
counterpart (ductal carcinoma in situ case number 57 and stage I, case numbers 4b and 233). Sequencing results of several independent clones 
are shown. Black circles, methylated CpG dinucleotides. Open brackets indicate the location of the BstUI restriction sites in the target sequence.Available online http://breast-cancer-research.com/content/11/1/R14
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cific methylated CpG islands are embedded in regions other
than promoters, consistent with the finding that the Polycomb
repressive complex 2 subunit SUZ12 is distributed across
large domains of developmental genes spanning from the pro-
moter up to 2 to 35 kb into the gene [46]. SUZ12 is required
for the histone methyltransferase activity and silencing func-
tion of the EED–EZH2 complex and is upregulated in different
tumors, including breast tumors [47]. EZH2, another key Poly-
comb repressor complex 2 component, undergoes gene
amplification in several tumor types [48] and is overexpressed
in prostate cancer and breast cancer [49,50]. EZH2 physically
interacts with all three DNA methyltransferases in mammalian
cells, and has been suggested to play a crucial role in regulat-
ing de novo DNA methylation and its maintenance at target
sequences [51].
Further support of this mechanistic connection between Poly-
comb silencing and tumor-associated DNA methylation comes
from recent studies linking Polycomb occupancy of genes in
noncancerous cells and tissues (including embryonic stem
cells) with cancer-associated hypermethylation events
[28,35,52-55]. Paradoxically, however, several homeobox
genes are upregulated rather than downregulated in breast
cancer and other tumor types, suggesting that several tiers of
regulation, other than DNA methylation, may concur in deter-
mining homeobox misregulation. Several genome-wide PcG
profiling studies have reported that 10% to 20% of the identi-
fied PcG targets are transcriptionally active [46,56,57].
Bracken and colleagues have suggested that, in undifferenti-
ated cells, PcG complexes have the potential to target genes
poised for silencing as well as target genes predisposed to
activation [57]. The transition between alternative modes of
PcG regulation may require additional signals upon differenti-
ation (and likewise during tumorigenesis), which may include
recruitment of additional transcriptional activators and/or com-
petition with PcG antagonists, the tritorax group (trxG) pro-
teins. These signals may all have a counteracting effect to the
PcG-mediated gene repression [57].
In a similar scenario, it is conceivable that many of the home-
obox gene-associated CpG islands that become methylated in
DCIS might have already switched off their active transcrip-
tional state in the normal breast epithelium or its progenitor
cells. If that were the case, a hypothesis linking DNA methyla-
tion of homeobox gene CpG islands mechanistically to tumor-
igenesis would not be sustainable. Unfortunately, no RNA
samples from DCIS were available to test the relationship
between DNA methylation and gene expression.
Conclusions
Our results strongly suggest that homeobox genes and other
developmental transcription factors become preferential tar-
gets of de novo methylation in DCIS. Aberrant methylation of
these master regulators may play a crucial role in the insur-
gence and/or progression of breast cancer.
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